Adjuvax LLC — Department of Health and Human Services SBIR Phase I: 106

Adjuvax LLC — SBIR Phase I award from Department of Health and Human Services.

Amount
$600,000
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase I
Topic
106
Solicitation
PHS-2022-1
NAICS
Place of performance
AL
Period

Description

AS01b (composed of the molecules QS-21 and MPL) is a powerful adjuvant best known for being a component of the FDA-approved Shingrix vaccine. Despite its successful track-record as an effective adjuvant, accessibility to AS01b as an adjuvant for use in novel vaccines is a concern due to the limited nature of the saponin molecule QS-21. The awardee seeks to address this problem by developing a mimic of AS01b by replacing QS-21 with a novel saponin molecule.